The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database "BE.Amycon data registry".
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Establishment of a data registry: participant baseline demographics
Timeframe: Baseline
Establishment of a data registry: description of the disease characteristics of patients with amyloidosis at diagnosis
Timeframe: Baseline
Establishment of a data registry: treatment in participants with amyloidosis
Timeframe: From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years
Establishment of a biobank with biological samples (blood, urine, tissue) from patients with amyloidosis
Timeframe: From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 2 years